KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 1.00

First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.

Xiaotian Zhang, Jufeng Wang, Gang Wang, Yanqiao Zhang, Qingxia Fan, Chuangxin Lu, Changlu Hu, Meili Sun, Yiye Wan, Sanyuan Sun, Junye Wang, Li Zhang, Yongqian Shu, Jie Luo, Dan Zhu, Zhenwei Shen, Sheng Yao, Qingmei Shi, Jason Yang, Lin Shen, GEMSTONE-303 Investigators

JAMA 333(15) 1305-1314

PMID39992668
PMCIDPMC11851304
DOI10.1001/jama.2024.28463
发表日期2025-02-24
入排依据:命中用户提供的消化道肿瘤阳性参考集。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

IMPORTANCE: Gastric cancer, including gastroesophageal junction cancer, is one of the most commonly diagnosed cancers worldwide, with high mortality. Sugemalimab is a fully human anti-programmed death-ligand 1 (PD-L1) antibody. The combination of sugemalimab and chemotherapy showed promising antitumor activity and safety in a phase 1b study among patients with treatment-naive, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This combination was further evaluated in the GEMSTONE-303 phase 3 trial. OBJECTIVE: To evaluate the efficacy of sugemalimab in combination with capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 combined positive score (CPS) of 5 or greater. DESIGN, SETTING, AND PARTICIPANTS: GEMSTONE 303 is a phase 3, randomized, double-blind, placebo-controlled study conducted at 54 sites in China that enrolled patients from April 9, 2019, through December 29, 2021, with follow-up to July 9, 2023. A total of 479 eligible patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS of 5 or greater who did not receive any prior systemic therapy were randomized. INTERVENTION: Patients received sugemalimab (1200 mg intravenously) (n = 241) or placebo (n = 238) every 3 weeks for up to 24 months, plus CAPOX every 3 weeks for up to 6 cycles. MAIN OUTCOMES AND MEASURES: Primary outcomes were overall survival and investigator-assessed progression-free survival. RESULTS: Baseline characteristics were well balanced between the 2 groups. Most patients were male (71.4% in sugemalimab group, 74.8% in placebo group). Median follow-up was 25.1 months in the sugemalimab group and 26.3 months in the placebo group. The sugemalimab group demonstrated significant improvements in overall survival (median, 15.6 months [95% CI, 13.3-17.8] vs 12.6 months [95% CI, 10.6-14.1]; hazard ratio, 0.75 [95% CI, 0.61-0.92]; P = .006) and progression-free survival (median, 7.6 months [95% CI, 6.4-7.9] vs 6.1 months [95% CI, 5.1-6.4]; hazard ratio, 0.66 [95% CI, 0.54-0.81]; P < .001). Grade 3 or higher treatment-related adverse events occurred in 53.9% of patients in the sugemalimab group and 50.6% in the placebo group. CONCLUSIONS AND RELEVANCE: Sugemalimab plus chemotherapy significantly prolonged overall survival and progression-free survival with a manageable safety profile in previously untreated patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03802591.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。